| Abstrakt: |
A recent study conducted in North Chicago, Illinois, has discovered a potential breakthrough in cancer immunotherapy. The study focuses on the protein tyrosine phosphatases PTPN2 and PTPN1, which play a crucial role in regulating inflammation. The researchers have developed a first-in-class inhibitor called ABBV-CLS-484 (AC484) that targets these proteins and has shown promising results in promoting anti-tumor immunity in mouse models of cancer resistant to PD-1 blockade. AC484 is currently being evaluated in patients with advanced solid tumors, and its efficacy is comparable to or even exceeds that of antibody-based immune checkpoint blockade. This research provides a new strategy for cancer immunotherapy and represents the first active-site phosphatase inhibitor to enter clinical evaluation for cancer treatment. [Extracted from the article] |
